P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH-RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL

• J. Panse,
• N. Daguindau,
• S. Okuyama,
• R. Peffault de Latour,
• P. Schafhausen,
• N. Straetmans,
• M. Al-Adhami,
• T. Ajayi,
• E. Persson,
• M. Yeh,
• R. Wong

Affiliations

J. Panse

1 Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany

N. Daguindau

2 Hematology Department, CH Annecy Genevois, Annecy, France

S. Okuyama

3 Hematology/Oncology Division, Denver Health Medical Center, Denver, United States of America

R. Peffault de Latour

4 French Reference Center for Aplastic Anemia and Paroxysmal Noctural Hemoglobinuria, Assistance Publique - Hôpitaux de Paris; Université de Paris, Paris, France

P. Schafhausen

5 Medical Clinic and Polyclinic II - Hematology, Oncology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

N. Straetmans

6 Department of Hematology, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium

M. Al-Adhami

7 Apellis Pharmaceuticals, Inc., Waltham, United States of America

T. Ajayi

7 Apellis Pharmaceuticals, Inc., Waltham, United States of America

E. Persson

8 Swedish Orphan Biovitrum AB, Stockholm, Sweden

M. Yeh

7 Apellis Pharmaceuticals, Inc., Waltham, United States of America

R. Wong

9 Sir Y.K. Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong